Orgenesis (ORGS) is a $35 million market cap biotechnology company that is committed to curing Type 1 Diabetes with a novel technology that combines cellular therapy and regenerative medicine.

Pall Corporation (PLL) is a $10 billon market cap company with a focus on manufacturing of cell therapies.

Orgenesis (ORGS) is a public company committed to curing type 1 diabetes with a breakthrough technology that combines cellular therapy and regenerative medicine – “Cellular Transdifferentiation.”

Professor Sarah Ferber and the research team at Orgenesis have successfully reprogrammed liver cells into fully functional Insulin Producing Cells (IPCs). They’ve had success curing diabetes in mice, and begin Phase 1 clinical trials in Type 1 diabetic patients in the next 12-15 months.

Initiating Coverage on Orgenesis, Inc. (ORGS) with $2.50 12-18 Month Target: Broad ORGS Patent for Turning Liver Cells into Insulin Producing Cells Creates a Potential Cure for Diabetes

Orgenesis SPRL, a subsidiary of Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and regenerative medicine, announced it has received the formal approval from the Walloon Region, Belgium (Service Public of Wallonia, DG06) for a EUR 2.15 million support program for the research and development of a potential cure for Type 1 Diabetes.

For hundreds of millions of Type 1 diabetics, Orgenesis’ (ORGS) patented treatment is the first real potential cure for their diabetes.

The key to Orgenesis’ work is a patented proprietary process called cellular trans-differentiation.

According to CEO Scott Kramer, “Cellular trans-differentiation causes one adult cell type -– in our case, an adult liver cell -– to directly transform into another adult cell type, a pancreatic islet or beta cell.”